Search

Your search keyword '"Matthews, Nik"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Matthews, Nik" Remove constraint Author: "Matthews, Nik" Database Unpaywall Remove constraint Database: Unpaywall
61 results on '"Matthews, Nik"'

Search Results

1. Data from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

2. Data from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

3. Supplementary Table S3 from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

4. Supplementary Methods, Tables S1 - S2, S4, Figures S1 - S11 from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

5. Supplementary Table S3 from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

6. Supplementary Methods, Tables S1 - S2, S4, Figures S1 - S11 from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

8. CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cells

9. Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma

10. Abstract 1960: Mechanisms of therapeutic synergy between pattern recognition response agonists and cdk4 inhibitors

12. The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing

13. Abstract PR06: Stabilising selection causes grossly altered but stable karyotypes in metastatic colorectal cancer

15. Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC)

16. Stabilising selection causes grossly altered but stable karyotypes in metastatic colorectal cancer

17. Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer

18. Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer

19. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

20. Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer

21. Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

22. Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma

23. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

24. CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.

25. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing

26. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

27. Abstract LB-094: Suppression of inflammatory gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

28. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal

29. Erratum: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

30. Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error corrected circulating tumour DNA sequencing

31. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

32. Tracking the Evolution of Non–Small-Cell Lung Cancer

33. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

36. iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.

39. The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity

43. Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

46. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

48. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

49. Abstract 983: Intratumor heterogeneity in non-small cell lung cancer inferred by multi-region exome sequencing

50. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution

Catalog

Books, media, physical & digital resources